Biomarkers of TRAEs in Patients With Advanced UC Treated With EV: Analysis of the UNITE Study

Amanda Nizam, MD, Cleveland Clinic, provides an overview of her recent research on biomarkers of treatment-related adverse events associated with enfortumab vedotin for advanced urothelial carcinoma. As part of a series of analyses of the UNITE study, Dr. Nizam shares what the identified biomarkers were and whether somatic gene alterations are strongly predictive of treatment-related toxicity for patients receiving this therapy.